Treatment of Hemorrhagic Fever with Renal Syndrome: Pathophysiologic Rationale and Practical Application
https://doi.org/10.20514/2226-6704-2025-15-4-252-261
EDN: LASKIO
Abstract
Current treatment of hemorrhagic fever with renal syndrome (HFRS) is primarily based on expert opinion and data from small observational studies, the results of which are not always confirmed in clinical practice. Due to the lack of effective antiviral agents for the treatment of HFRS, the search for optimal supportive therapy continues. The clinical course of HFRS is characterized by the sequential development of phases of fever, hypotension, oliguria, polyuria and convalescence; each of these phases is characterized by certain pathophysiological mechanisms, knowledge of which is necessary for the correct management of patients with HFRS. This narrative review provides the pathophysilogic rationale and practical experience of using treatment methods for HFRS, such as anti-inflammatory therapy, correction of fluid, electrolyte, hemodynamic and hemocoagulation disorders, as well as, renal replacement therapy and symptomatic therapy.
Supporting agencies: The authors declare no funding for this study
About the Author
O. V. Malinin
Izhevsk State Medical Academy
Russian Federation
Competing Interests:
Russian Federation
Oleg V. Malinin — Cand. Sci. (Med.), Head of the Department of Infectious Diseases and Epidemiology
Izhevsk
Competing Interests:
The authors declare no conflict of interests
References
1. Vial P.A, Ferrés M., Vial C. et al. Hantavirus in humans: a review of clinical aspects and management. Lancet Infect Dis. 2023;23(9):e371-e382. doi: 10.1016/S1473-3099(23)00128-7
2. Arbuzova T.V., Gladkikh A.S., Tokarevich N.K. et al. Hemorrhagic fever with renal syndrome: epidemic situation in the Russian Federation. Infekc. bolezni (Infectious Diseases). 2024;22(3):66-75. doi: 10.20953/1729-9225-2024-3-66-75 [In Russian].
3. Dzagurova T.K., Siniugina A.A., Ishmukhametov A.A. et al. Pre-Clinical Studies of Inactivated Polyvalent HFRS Vaccine. Front Cell Infect Microbiol. 2020;10:545372. doi: 10.3389/fcimb.2020.545372.
4. Huggins J.W., Hsiang C.M., Cosgriff T.M. et al. Prospective, doubleblind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. J Infect Dis. 1991;164(6):1119-1127. doi: 10.1093/infdis/164.6.1119
5. Malinin O.V., Platonov A.E. Insufficient efficacy and safety of intravenous ribavirin in treatment of haemorrhagic fever with renal syndrome caused by Puumala virus. Infect Dis (Lond). 2017;49(7):514-520. doi: 10.1080/23744235.2017.1293841
6. Mertz G.J., Miedzinski L., Goade D. et al. Placebo-controlled, doubleblind trial of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America. Clin Infect Dis. 2004;39(9):1307-1313. doi: 10.1086/425007
7. Vial P.A., Valdivieso F., Ferres M. et al. High-dose intravenous methylprednisolone for hantavirus cardiopulmonary syndrome in Chile: a double-blind, randomized controlled clinical trial. Clin Infect Dis. 2013;57(7):943-951. doi: 10.1093/cid/cit394
8. Wagner R., Leicht-Biener U., Mucsi I. et al. Ibuprofen or diclofenac is associated with more severe acute kidney injury in nephropathia epidemica. Scand J Urol Nephrol. 2012;46(1):65-69. doi: 10.3109/00365599.2011.625041
9. Noack D., Goeijenbier M., Reusken C.B.E.M. et al. Orthohantavirus Pathogenesis and Cell Tropism. Front Cell Infect Microbiol. 2020;10:399. doi: 10.3389/fcimb.2020.00399
10. Sehgal A., Mehta S., Sahay K. et al. Hemorrhagic Fever with Renal Syndrome in Asia: History, Pathogenesis, Diagnosis, Treatment, and Prevention. Viruses. 2023;15(2):561. doi: 10.3390/v15020561
11. Mittler E., Wec A.Z., Tynell J. et al. Human antibody recognizing a quaternary epitope in the Puumala virus glycoprotein provides broad protection against orthohantaviruses. Sci Transl Med. 2022;14(636):eabl5399. doi: 10.1126/scitranslmed.abl5399
12. Safronetz D., Falzarano D., Scott D.P. et al. Antiviral efficacy of favipiravir against two prominent etiological agents of hantavirus pulmonary syndrome. Antimicrob Agents Chemother. 2013;57(10):4673-4680. doi: 10.1128/AAC.00886-13
13. Klingström J., Smed-Sörensen A., Maleki K.T. et al. Innate and adaptive immune responses against human Puumala virus infection: immunopathogenesis and suggestions for novel treatment strategies for severe hantavirus-associated syndromes. J Intern Med. 2019;285(5):510-523. doi: 10.1111/joim.12876
14. Yao L., Wang X., Wang Z. et al. Comprehensive Analysis Exploring the Vital Role of the Systemic Immune-Inflammatory Index Upon Admission in Severe Hemorrhagic Fever with Renal Syndrome. Int J Gen Med. 2024;17:4857-4866. doi: 10.2147/IJGM.S480204
15. Malinina G.A., Riabov V.I., Malinin O.V. The functional activity of neutrophilic granulocytes in hemorrhagic fever with renal syndrome. Zh Mikrobiol Epidemiol Immunobiol. 1994;71(1):100-103. [In Russian].
16. Schönrich G., Krüger D.H., Raftery M.J. Hantavirus-induced disruption of the endothelial barrier: neutrophils are on the payroll. Front Microbiol. 2015;6:222. doi: 10.3389/fmicb.2015.00222
17. Outinen T.K., Mäkelä S., Pörsti I. et al. Severity Biomarkers in Puumala Hantavirus Infection. Viruses. 2021;14(1):45. doi: 10.3390/v14010045
18. Malinin O.V., Kiryanov N.A.. Fatal cases of hemorrhagic fever with renal syndrome in Udmurtia, Russia, 2010 to 2019. Eur J Clin Microbiol Infect Dis. 2022;41(7):1059-1064. doi: 10.1007/s10096-022-04463-y
19. Koskela S., Mäkelä S., Strandin T. et al. Coagulopathy in Acute Puumala Hantavirus Infection. Viruses. 2021;13(8):1553. doi: 10.3390/v13081553
20. Evander M., Eriksson I., Pettersson L. et al. Puumala hantavirus viremia diagnosed by real-time reverse transcriptase PCR using samples from patients with hemorrhagic fever and renal syndrome. J Clin Microbiol. 2007;45(8):2491-2497. doi: 10.1128/JCM.01902-06
21. Pettersson L., Thunberg T., Rocklöv J. et al. Viral load and humoral immune response in association with disease severity in Puumala hantavirus-infected patients--implications for treatment. Clin Microbiol Infect. 2014 Mar;20(3):235-241. doi: 10.1111/1469-0691.12259
22. Yi J., Xu Z., Zhuang R. et al. Hantaan virus RNA load in patients having hemorrhagic fever with renal syndrome: correlation with disease severity. J Infect Dis. 2013 May 1;207(9):1457-1461. doi: 10.1093/infdis/jis475
23. Chen W.J., Du H., Hu H.F. et al. Levels of peripheral blood routine, biochemical and coagulation parameters in patients with hemorrhagic fever with renal syndrome and their relationship with prognosis: an observational cohort study. BMC Infect Dis. 2024;24(1):75. doi: 10.1186/s12879-023-08777-w
24. Shiri P., Rezaeian S., Abdi A. et al. Prevalence of thrombosis in patients undergoing dialysis treatment: A systematic review and meta-analysis. J Vasc Nurs. 2024;42(4):251-263. doi: 10.1016/j.jvn.2024.08.003
25. Engelen M.M., Verhamme P., Vanassche T. Clotting of the Extracorporeal Circuit in Hemodialysis: Beyond Contact-Activated Coagulation. Semin Nephrol. 2023;43(6):151473. doi: 10.1016/j.semnephrol.2023.151473
26. Mustonen J., Outinen T., Laine O. et al. Kidney disease in Puumala hantavirus infection. Infect Dis (Lond). 2017;49(5):321-332. doi: 10.1080/23744235.2016.1274421
27. Koehler F.C., Di Cristanziano V., Späth M.R. et al. The kidney in hantavirus infection-epidemiology, virology, pathophysiology, clinical presentation, diagnosis and management. Clin Kidney J. 2022;15(7):1231-1252. doi: 10.1093/ckj/sfac008
28. Gnemmi V., Verine J., Vrigneaud L. et al. Microvascular inflammation and acute tubular necrosis are major histologic features of hantavirus nephropathy. Hum Pathol. 2015;46(6):827-835. doi: 10.1016/j.humpath.2015.02.002
29. Malinin O.V., Dyachenko I.I., Mihaylov S.V. et al. Complications of hemorrhagic fever with renal syndrome: prevention, diagnostics and therapy. In the book: Infectious diseases in the modern world: epidemiology, diagnostics, treatment and prevention. Collection of works of the XII Annual National Internet Congress on Infectious Diseases. Moscow, 2020; 140. [In Russian].
30. Jiang H., Huang C., Bai X. et al. Expert consensus on the prevention and treatment of hemorrhagic fever with renal syndrome. Infect Dis Immun 2022;2(4):224-232. doi: 10.1097/ID9.0000000000000054
31. Brocato R.L., Hooper J.W. Progress on the Prevention and Treatment of Hantavirus Disease. Viruses. 2019;11(7):610. doi: 10.3390/v11070610
32. Afzal S., Ali L., Batool A. et al. Hantavirus: an overview and advancements in therapeutic approaches for infection. Front Microbiol. 2023;14:1233433. doi: 10.3389/fmicb.2023.1233433
33. Sayer W.J., Entwhisle G., Uyeno B. et al. Cortisone therapy of early epidemic hemorrhagic fever: a preliminary report. Ann Intern Med. 1955;42(4):839-851. doi: 10.7326/0003-4819-42-4-839
34. Antonen J., Leppänen I., Tenhunen J. et al. A severe case of Puumala hantavirus infection successfully treated with bradykinin receptor antagonist icatibant. Scand J Infect Dis. 2013;45(6):494-496. doi: 10.3109/00365548.2012.755268
35. Vaheri A., Strandin T., Jääskeläinen A.J. et al. Pathophysiology of a severe case of Puumala hantavirus infection successfully treated with bradykinin receptor antagonist icatibant. Antiviral Res. 2014;111:23-25. doi: 10.1016/j.antiviral.2014.08.007
36. Mustonen J., Antonen J., Vaheri A. Icatibant in viral infections. Infect Dis (Lond). 2023;55(6):444-445. doi: 10.1080/23744235.2023.2200563
37. Ministry of Health of the Russian Federation. Sepsis (in adults): Clinical guidelines. 2024. [Electronic resource]. URL: https://cr.minzdrav.gov.ru/view-cr/898_1. (date of the application: 25.04.2025). [In Russian].
38. Seitsonen E., Hynninen M., Kolho E. et al. Corticosteroids combined with continuous veno-venous hemodiafiltration for treatment of hantavirus pulmonary syndrome caused by Puumala virus infection. Eur J Clin Microbiol Infect Dis. 2006;25(4):261-266. doi: 10.1007/s10096-006-0117-z
39. López R., Pérez-Araos R., Salazar Á. et al. Targeted high volume hemofiltration could avoid extracorporeal membrane oxygenation in some patients with severe Hantavirus cardiopulmonary syndrome. J Med Virol. 2021;93(8):4738-4747. doi: 10.1002/jmv.26930
40. Chen H., Li Y., Zhang P. et al. A case report of empty Sella syndrome secondary to Hantaan virus infection and review of the literature. Medicine (Baltimore). 2020;99(14):e19734. doi: 10.1097/MD.0000000000019734
41. Pastissier A., Humbert S., Naudion P. et al. Severe Sinus Bradycardia in Puumala virus infection. Int J Infect Dis. 2019;79:75-76. doi: 10.1016/j.ijid.2018.11.019
42. Tkachenko E., Balkina A., Trankvilevsky D. et al. The Specificity of Epizootic and Epidemiological Processes in Natural Foci of Hemorrhagic Fever with Renal Syndrome and Tick-Borne Encephalitis in Russia, as the Basis for the Prospects of Creating a Combined Vaccine for the Prevention of These Infections. Viruses. 2024;16(8):1292. doi: 10.3390/v16081292
43. Piton G., Cypriani B., Regnard J. et al. Catecholamine use is associated with enterocyte damage in critically ill patients. Shock. 2015;43(5):437-442. doi: 10.1097/SHK.0000000000000327
44. Habes Q.L.M., van Ede L., Gerretsen J. et al. Norepinephrine Contributes to Enterocyte Damage in Septic Shock Patients: A Prospective Cohort Study. Shock. 2018;49(2):137-143. doi: 10.1097/SHK.0000000000000955
Review
For citations:
Malinin O.V. Treatment of Hemorrhagic Fever with Renal Syndrome: Pathophysiologic Rationale and Practical Application. The Russian Archives of Internal Medicine. 2025;15(4):252-261. (In Russ.) https://doi.org/10.20514/2226-6704-2025-15-4-252-261. EDN: LASKIO
Views:
70
Email this article 